NR1H4 and metabolic dysfunction-associated steatotic liver disease: FXR is used as a target for new drug therapies against metabolic dysregulation associated with obesity, including type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and atherosclerosis as well as for the cholestatic liver disease primary biliary cholangitis4–7.